

Special Issue

Advances in Research on Human Meningiomas

Message from the Guest Editors

This Special Issue deals with human meningiomas, which are mostly benign and slow-growing tumors. Their biology can, however, be capricious as some cases recur despite a benign histology. Thus, the histopathological grading system of these tumors is suboptimal, and more objective diagnostic and prognostic biomarkers are required. For instance, methylation-based tumor classification is highly relevant. For most meningioma patients treated with optimal surgical and radiation approaches, outcomes are good. Unfortunately, some of these tumors cannot be totally resected, and some may recur even after complete resection and radiotherapy. Furthermore, both surgery and radiotherapy may have troublesome and serious complications. Accordingly, this Special Issue welcomes papers on biomarkers that can improve our diagnostic and prognostic work-up of these tumors.

Guest Editors

Prof. Dr. Sverre Helge Torp

1. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
2. Department of Pathology, St. Olavs Hospital, 7006 Trondheim, Norway

Dr. David Scheie

Department of Pathology, Righospitalet, Copenhagen University Hospital. Frederik Vs vej 11, 2100 Copenhagen, Denmark

Deadline for manuscript submissions

closed (1 July 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/57888

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)